JN International acquires vaccine facilities from Pfizer
JN International, a biopharmaceutical company, is to expand its ability to increase vaccines supplies by acquiring a vaccine research and production facility from Biocor, a subsidiary of Pfizer, in Omaha, Nebraska.
JN International, a biopharmaceutical company, is to expand its ability to increase vaccines supplies by acquiring a vaccine research and production facility from Biocor, a subsidiary of Pfizer, in Omaha, Nebraska.
The vaccine manufacturing facility consists of three buildings with a total combined space of approximately 80,000sq ft. These facilities were purpose-built for vaccine manufacture.
Dr Jeeri Reddy, JN International's president and scientific director, said the purchase represents a "significant capital investment", which is intended to help significantly reduce time-to-market for the firm's meningococcal meningitis serotypes A, C, Y & W-135 vaccine and increase production capacity to meet the demand of sub-Saharan Africa and South East Asia.
Dr Noel Kouame, medical director of JN-International in Cote d'Ivoire added: "The supply of meningococcal vaccines, be it in response to a pandemic or seasonal outbreaks in Africa, requires robust production processes supported by manufacturers with stringent supply chain routines and quality systems who are able to react quickly to the demand."